symbol,statement_type,period_end,line_item,value
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Free Cash Flow,-1123169000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Issuance Of Capital Stock,43000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Capital Expenditure,-4438784000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,End Cash Position,67337000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Beginning Cash Position,236349000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Changes In Cash,-169012000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Financing Cash Flow,654350000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net Other Financing Charges,
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Interest Paid Cff,-245115000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Cash Dividends Paid,-317191000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net Common Stock Issuance,43000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Common Stock Issuance,43000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net Issuance Payments Of Debt,1278608000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net Short Term Debt Issuance,278608000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net Long Term Debt Issuance,1000000000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Investing Cash Flow,-4138977000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net Other Investing Changes,1000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Interest Received Cfi,70961000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Dividends Received Cfi,507000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net Investment Purchase And Sale,228338000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Sale Of Investment,
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of Investment,
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net Intangibles Purchase And Sale,-418410000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of Intangibles,-418410000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net PPE Purchase And Sale,-4020374000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Purchase Of PPE,-4020374000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Operating Cash Flow,3315615000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Taxes Refund Paid,-645266000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Working Capital,-860664000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Other Current Assets,
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Payable,-569125000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Inventory,552790000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Change In Receivables,-844329000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Other Non Cash Items,198003000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Provisionand Write Offof Assets,12814000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Depreciation And Amortization,869040000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Amortization Cash Flow,
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Depreciation,869040000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Gain Loss On Investment Securities,-507000.0
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Gain Loss On Sale Of PPE,
AARTIPHARM.NS,cashflow,2025-03-31 00:00:00,Net Income From Continuing Operations,3606895000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Free Cash Flow,175695000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Issuance Of Capital Stock,0.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Capital Expenditure,-1987851000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,End Cash Position,236349000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Beginning Cash Position,121212000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Changes In Cash,115137000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Financing Cash Flow,97235000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net Other Financing Charges,-1000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Interest Paid Cff,-172147000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Cash Dividends Paid,-181252000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net Common Stock Issuance,0.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Common Stock Issuance,0.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net Issuance Payments Of Debt,499935000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net Short Term Debt Issuance,499935000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net Long Term Debt Issuance,0.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Investing Cash Flow,-2145644000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net Other Investing Changes,5506000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Interest Received Cfi,30419000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Dividends Received Cfi,321000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net Investment Purchase And Sale,-194039000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Sale Of Investment,5506000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of Investment,-194039000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net Intangibles Purchase And Sale,-431809000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of Intangibles,-431809000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net PPE Purchase And Sale,-1556042000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Purchase Of PPE,-1556042000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Operating Cash Flow,2163546000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Taxes Refund Paid,-569370000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Working Capital,-1218506000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Other Current Assets,
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Payable,433484000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Inventory,-396636000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Change In Receivables,-1255354000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Other Non Cash Items,141728000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Provisionand Write Offof Assets,10676000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Depreciation And Amortization,732353000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Amortization Cash Flow,12700000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Depreciation,732353000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Gain Loss On Investment Securities,-321000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Gain Loss On Sale Of PPE,-5506000.0
AARTIPHARM.NS,cashflow,2024-03-31 00:00:00,Net Income From Continuing Operations,3004919000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Free Cash Flow,1304585000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Issuance Of Capital Stock,
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Capital Expenditure,-1196569000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,End Cash Position,121212000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,52000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Beginning Cash Position,832734000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Changes In Cash,-711522000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Financing Cash Flow,-1634646000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net Other Financing Charges,100000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Interest Paid Cff,-210517000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Cash Dividends Paid,-181252000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net Common Stock Issuance,
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Common Stock Issuance,
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net Issuance Payments Of Debt,-1242877000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net Short Term Debt Issuance,-1242877000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net Long Term Debt Issuance,-1242900000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Investing Cash Flow,-1578030000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net Other Investing Changes,-1000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Interest Received Cfi,9373000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Dividends Received Cfi,400000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net Investment Purchase And Sale,-391233000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Sale Of Investment,
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of Investment,-391233000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net Intangibles Purchase And Sale,-175286000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of Intangibles,-175286000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net PPE Purchase And Sale,-1021283000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Purchase Of PPE,-1021300000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Operating Cash Flow,2501154000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Taxes Refund Paid,-623827000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Working Capital,-316315000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Other Current Assets,
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Payable,1302026000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Inventory,-1266622000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Change In Receivables,-351719000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Other Non Cash Items,201144000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Provisionand Write Offof Assets,15000000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Depreciation And Amortization,625427000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Amortization Cash Flow,443000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Depreciation,624984000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Gain Loss On Investment Securities,-8022000.0
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Gain Loss On Sale Of PPE,
AARTIPHARM.NS,cashflow,2023-03-31 00:00:00,Net Income From Continuing Operations,2607747000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Free Cash Flow,-1848558000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Issuance Of Capital Stock,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Capital Expenditure,-1411520000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,End Cash Position,832734000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,16000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Beginning Cash Position,53311000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Changes In Cash,779407000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Financing Cash Flow,2603834000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net Other Financing Charges,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Interest Paid Cff,-119588000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Cash Dividends Paid,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net Common Stock Issuance,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Common Stock Issuance,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net Issuance Payments Of Debt,2723422000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net Short Term Debt Issuance,2723422000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net Long Term Debt Issuance,2723400000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Investing Cash Flow,-1387389000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net Other Investing Changes,300000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Interest Received Cfi,76000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Dividends Received Cfi,24786000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net Investment Purchase And Sale,-731000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Sale Of Investment,401000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of Investment,-1132000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net Intangibles Purchase And Sale,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of Intangibles,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net PPE Purchase And Sale,-1411520000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Purchase Of PPE,-1411500000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Operating Cash Flow,-437038000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Taxes Refund Paid,-211293000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Working Capital,-2303632000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Other Current Assets,-260223.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Payable,-718620000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Inventory,-559920000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Change In Receivables,-1025092000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Other Non Cash Items,128084000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Provisionand Write Offof Assets,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Depreciation And Amortization,421186000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Amortization Cash Flow,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Depreciation,421186000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Gain Loss On Investment Securities,-25187000.0
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Gain Loss On Sale Of PPE,
AARTIPHARM.NS,cashflow,2022-03-31 00:00:00,Net Income From Continuing Operations,1553804000.0
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Free Cash Flow,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Issuance Of Capital Stock,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Capital Expenditure,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,End Cash Position,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Beginning Cash Position,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Changes In Cash,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Financing Cash Flow,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net Other Financing Charges,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Interest Paid Cff,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Cash Dividends Paid,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net Common Stock Issuance,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Common Stock Issuance,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net Issuance Payments Of Debt,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net Short Term Debt Issuance,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net Long Term Debt Issuance,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Investing Cash Flow,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net Other Investing Changes,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Interest Received Cfi,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Dividends Received Cfi,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net Investment Purchase And Sale,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Sale Of Investment,0.0
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of Investment,0.0
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net Intangibles Purchase And Sale,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of Intangibles,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net PPE Purchase And Sale,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Purchase Of PPE,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Operating Cash Flow,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Taxes Refund Paid,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Working Capital,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Other Current Assets,45960.0
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Payable,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Inventory,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Change In Receivables,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Other Non Cash Items,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Provisionand Write Offof Assets,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Depreciation And Amortization,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Amortization Cash Flow,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Depreciation,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Gain Loss On Investment Securities,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Gain Loss On Sale Of PPE,
AARTIPHARM.NS,cashflow,2021-03-31 00:00:00,Net Income From Continuing Operations,
